HC Wainwright & Co. Reiterates Buy on SAB Biotherapeutics, Adjusts Price Target To $10
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Edward White has reiterated a Buy rating on SAB Biotherapeutics (NASDAQ:SABS) and adjusted the price target from $1 to $10.
January 08, 2024 | 11:22 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Edward White reaffirmed a Buy rating on SAB Biotherapeutics and increased the price target from $1 to $10.
The reiteration of a Buy rating combined with a significant increase in the price target from $1 to $10 by a reputable analyst is likely to instill confidence in investors and could lead to a short-term increase in the stock price of SAB Biotherapeutics.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100